RiverPark Advisors’s Edwards Lifesciences EW Stock Holding History

RiverPark Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$700K	Sell	8,737 -525	-6%	-$43.3K	0.25%	66
2025 Q4	$790K	Sell	9,262 -835	-8%	-$68.5K	0.23%	72
2025 Q3	$785K	Sell	10,097 -70	-0.7%	-$5.47K	0.34%	54
2025 Q2	$795K	Sell	10,167 -9,822	-49%	-$733K	0.49%	48
2025 Q1	$1.45M	Hold	19,989	–	–	1.13%	31
2024 Q4	$1.48M	Sell	19,989 -650	-3%	-$45.5K	1.18%	27
2024 Q3	$1.36M	Buy	20,639 +7,583	+58%	+$551K	1.11%	31
2024 Q2	$1.21M	Hold	13,056	–	–	1%	33
2024 Q1	$1.25M	Sell	13,056 -2,655	-17%	-$223K	1.03%	35
2023 Q4	$1.2M	Buy	15,711 +2,716	+21%	+$189K	1.1%	37
2023 Q3	$900K	Buy	12,995 +150	+1%	+$12.1K	0.81%	42
2023 Q2	$1.21M	Sell	12,845 -505	-4%	-$43.9K	1.11%	39
2023 Q1	$1.1M	Sell	13,350 -325	-2%	-$25.5K	0.74%	46
2022 Q4	$1.02M	Sell	13,675 -1,515	-10%	-$117K	0.49%	68
2022 Q3	$1.25M	Sell	15,190 -500	-3%	-$48.1K	0.41%	79
2022 Q2	$1.49M	Sell	15,690 -250	-2%	-$25.9K	0.47%	63
2022 Q1	$1.88M	Sell	15,940 -1,200	-7%	-$135K	0.34%	64
2021 Q4	$2.22M	Sell	17,140 -9,015	-34%	-$1.05M	0.27%	68
2021 Q3	$2.96M	Hold	26,155	–	–	0.36%	58
2021 Q2	$2.71M	Sell	26,155 -2,100	-7%	-$198K	0.35%	57
2021 Q1	$2.36M	Sell	28,255 -7,135	-20%	-$603K	0.39%	45
2020 Q4	$3.23M	Sell	35,390 -5,745	-14%	-$477K	0.57%	38
2020 Q3	$3.28M	Sell	41,135 -4,175	-9%	-$326K	0.74%	39
2020 Q2	$3.13M	Sell	45,310 -24,500	-35%	-$1.74M	0.97%	40
2020 Q1	$4.39M	Sell	69,810 -49,875	-42%	-$3.6M	2.51%	12
2019 Q4	$9.31M	Sell	119,685 -1,083	-0.9%	-$84.6K	3.92%	5
2019 Q3	$8.85M	Sell	120,768 -14,970	-11%	-$1.05M	4.03%	5
2019 Q2	$8.36M	Sell	135,738 -21,300	-14%	-$1.29M	3.59%	5
2019 Q1	$10M	Sell	157,038 -31,800	-17%	-$1.81M	4.35%	4
2018 Q4	$9.64M	Sell	188,838 -131,250	-41%	-$6.64M	4.23%	6
2018 Q3	$18.6M	Sell	320,088 -104,412	-25%	-$5.11M	4.45%	6
2018 Q2	$20.6M	Sell	424,500 -64,500	-13%	-$3.01M	4.17%	8
2018 Q1	$22.7M	Sell	489,000 -319,500	-40%	-$13.9M	4.38%	6
2017 Q4	$30.4M	Sell	808,500 -52,500	-6%	-$1.93M	4.35%	6
2017 Q3	$31.4M	Buy	861,000 +396,000	+85%	+$15.1M	4.13%	10
2017 Q2	$18.3M	Sell	465,000 -711,000	-60%	-$26M	2.09%	20
2017 Q1	$36.9M	Buy	+1,176,000	New	+$36.8M	2.43%	19
2014 Q2	–	Sell	-78,732	Closed	-$973K	–	49
2014 Q1	$973K	Sell	78,732 -26,544	-25%	-$306K	0.5%	45
2013 Q4	$1.15M	Hold	105,276	–	–	0.76%	42
2013 Q3	$1.22M	Buy	105,276 +25,152	+31%	+$294K	0.91%	40
2013 Q2	$897K	Buy	+80,124	New	+$948K	0.77%	42

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RiverPark Advisors's EW Position: Q1 2026 in Review

RiverPark Advisors reduced its Edwards Lifesciences (EW) stake by 5.7% in Q1 2026, selling an estimated $43.3K and leaving 8,737 shares worth $700K. The position accounts for 0.25% of the portfolio, ranked #66.

RiverPark Advisors first reported a position in EW in Q2 2013 and has held it in 41 quarters since. The position peaked at $36.9M in Q1 2017. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

RiverPark Advisors held 8,737 shares of Edwards Lifesciences worth $700K as of Q1 2026.
RiverPark Advisors sold 525 Edwards Lifesciences shares in Q1 2026, an estimated $43.3K.
Edwards Lifesciences made up 0.25% of RiverPark Advisors's portfolio in Q1 2026, its #66 holding.
RiverPark Advisors first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 41 quarters since.
RiverPark Advisors's Edwards Lifesciences position peaked at $36.9M in Q1 2017.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on RiverPark Advisors's 13F filing for Q1 2026, filed 14 May 2026.